<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02031536</url>
  </required_header>
  <id_info>
    <org_study_id>E2212</org_study_id>
    <secondary_id>NCI-2013-02484</secondary_id>
    <secondary_id>ECOG-E2212</secondary_id>
    <secondary_id>U10CA021115</secondary_id>
    <nct_id>NCT02031536</nct_id>
  </id_info>
  <brief_title>Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery</brief_title>
  <official_title>A Randomized, Double-Blinded, Placebo-Controlled Phase II Study of Adjuvant Everolimus Following the Resection of Metastatic Pancreatic Neuroendocrine Tumors to the Liver</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ECOG-ACRIN Cancer Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Eastern Cooperative Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase II trial studies how well everolimus works in treating patients with&#xD;
      pancreatic neuroendocrine tumors metastatic to the liver previously treated with surgery.&#xD;
      Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell&#xD;
      growth. Giving everolimus after surgery may kill any tumors cells that remain.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate if the addition of adjuvant everolimus to the R0 or R1 surgical resection of&#xD;
      pancreatic neuroendocrine tumor metastases to the liver will result in an improvement in&#xD;
      disease free survival.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate if the addition of adjuvant everolimus to the R0 or R1 surgical resection of&#xD;
      pancreatic neuroendocrine tumor metastases to the liver will result in an improvement in&#xD;
      overall survival.&#xD;
&#xD;
      II. To evaluate the toxicity associated with adjuvant everolimus following resection in&#xD;
      patients with metastatic pancreatic neuroendocrine tumors to the liver.&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 2 treatment arms in a 1:1 ratio.&#xD;
&#xD;
      ARM A: Patients receive everolimus orally (PO) once daily (QD) on days 1-28. Treatment&#xD;
      repeats every 28 days for up to 12 courses in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      ARM B: Patients receive placebo PO QD on days 1-28. Treatment repeats every 28 days for up to&#xD;
      12 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 3 months for 2 years and&#xD;
      then every 6 months for 3 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: 150 patients&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow accrual&#xD;
  </why_stopped>
  <start_date type="Actual">January 17, 2014</start_date>
  <completion_date type="Actual">July 19, 2017</completion_date>
  <primary_completion_date type="Actual">July 19, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Free Survival (DFS)</measure>
    <time_frame>assessed every 12 weeks while on treatment and then every 3 months if &lt; 2 years from study entry; every 6 months up to 5 years from study entry or recurrence, whichever occurred first</time_frame>
    <description>DFS is defined as time from randomization to disease recurrence or death, whichever occurred first. Patients who are still alive are censored at the last date of known free of recurrence.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>assessed every 3 months if &lt; 2 years from study entry, and every 6 months up to 5 years from study entry or death, whichever occurred first</time_frame>
    <description>OS is defined as time from randomization to death from any cause. Patients who are still alive are censored at the last date of known alive.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Gastrinoma</condition>
  <condition>Glucagonoma</condition>
  <condition>Insulinoma</condition>
  <condition>Liver Metastases</condition>
  <condition>Pancreatic Polypeptide Tumor</condition>
  <condition>Recurrent Islet Cell Carcinoma</condition>
  <condition>Somatostatinoma</condition>
  <arm_group>
    <arm_group_label>Arm A (everolimus)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive everolimus PO QD on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive placebo PO QD on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>everolimus</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm A (everolimus)</arm_group_label>
    <other_name>42-O-(2-hydroxy)ethyl rapamycin</other_name>
    <other_name>Afinitor</other_name>
    <other_name>RAD001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm B (placebo)</arm_group_label>
    <other_name>PLCB</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:&#xD;
&#xD;
          -  Patients must have histologically or pathologically confirmed metastatic low or&#xD;
             intermediate grade pancreatic neuroendocrine tumor(s) to the liver as per the Klimstra&#xD;
             guidelines&#xD;
&#xD;
          -  Patients must have recovered from an R0 or R1 resection of all disease (including&#xD;
             resection of a primary primitive neuroectodermal tumor [PNET] if present); patients&#xD;
             may have had resection plus microwave or radiofrequency ablation, provided that no&#xD;
             ablated lesion was &gt;= 5 cm prior to ablation&#xD;
&#xD;
          -  Patients must be within 4 to 8 weeks from the completion of surgery at time of&#xD;
             randomization&#xD;
&#xD;
          -  Patients must have paraffin-embedded fixed metastatic tumor tissue available for&#xD;
             submission for central review; core biopsy or surgical specimens required&#xD;
&#xD;
          -  Patients must have post-operative computed tomography (CT) or magnetic resonance&#xD;
             imaging (MRI) prior to randomization and =&lt; 4 weeks after completion of surgery to&#xD;
             confirm disease status; patients must be able to tolerate CT or MRI imaging including&#xD;
             contrast agents as required for the protocol&#xD;
&#xD;
          -  Women of child-bearing potential and sexually active males must be strongly advised to&#xD;
             use an accepted and highly effective method of contraception or abstain from sexual&#xD;
             intercourse for the duration of their treatment through 8 weeks after their last dose&#xD;
             of protocol therapy; women of child-bearing potential, sexually active males, and the&#xD;
             female partners of male participants should be advised of the risk of becoming&#xD;
             pregnant or fathering a child while receiving protocol treatment; should a woman&#xD;
             become pregnant while participating in this study, she should inform her treating&#xD;
             physician immediately; if a man impregnates a woman while participating in this study,&#xD;
             he should inform his treating physician immediately&#xD;
&#xD;
          -  Prior treatment with sunitinib and/or cytotoxic chemotherapy are allowed provided last&#xD;
             dose was &gt; 30 days prior to randomization&#xD;
&#xD;
          -  Prior chemoembolization is allowed provided last dose was &gt; 30 days prior to&#xD;
             randomization&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 X institutional upper limit of normal (ULN)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase&#xD;
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])&#xD;
             =&lt; 5 X institutional ULN&#xD;
&#xD;
          -  Serum creatinine =&lt; 1.5 X institutional ULN or creatinine clearance &gt;= 60 mL/min for&#xD;
             patients with creatinine levels above 1.5 X institutional normal&#xD;
&#xD;
          -  Fasting serum cholesterol =&lt; 300 mg/dL OR =&lt; 7.75 mmol/L AND fasting triglycerides =&lt;&#xD;
             2.5 x ULN&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1,500/mm^3&#xD;
&#xD;
          -  Leukocytes &gt;= 3,000/mm^3&#xD;
&#xD;
          -  Platelets &gt;= 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin &gt;= 9 g/dL&#xD;
&#xD;
          -  Patients with a history of the following within =&lt; 12 months of randomization are not&#xD;
             eligible&#xD;
&#xD;
               -  Arterial thromboembolic events&#xD;
&#xD;
               -  Unstable angina&#xD;
&#xD;
               -  Myocardial infarction&#xD;
&#xD;
          -  Patients with known history of abnormal pulmonary function must have documentation of&#xD;
             diffusing capacity of the lung for carbon monoxide (DLCO) of &gt; 50% predicted and&#xD;
             oxygen saturation (SaO2) of &gt; 87% at rest on room air =&lt; 4 weeks prior to&#xD;
             randomization&#xD;
&#xD;
          -  Patients with unexplained pulmonary infiltrates must have pulmonary function tests&#xD;
             within the institutional limits of normal =&lt; 4 weeks prior to randomization&#xD;
&#xD;
          -  Patients with poorly controlled diabetes mellitus as defined by hemoglobin A1c (HbA1c)&#xD;
             &gt; 8% despite adequate therapy are ineligible; patients with a known history of&#xD;
             impaired fasting glucose or diabetes mellitus must have blood glucose and antidiabetic&#xD;
             treatment monitored closely throughout the trial and adjusted as necessary&#xD;
&#xD;
          -  Patients may not be receiving any other investigational agents while on study&#xD;
             treatment; prior treatment with other investigational agent is allowed provided last&#xD;
             dose was &gt;= 30 days prior to randomization&#xD;
&#xD;
          -  Patients must NOT have received live attenuated vaccines =&lt; 1 week prior to&#xD;
             randomization; patients should also be advised not to receive live attenuated vaccines&#xD;
             during the study and to avoid close contact with others who have received live&#xD;
             attenuated vaccines; examples of live attenuated vaccines include intranasal&#xD;
             influenza, measles, mumps, rubella, oral polio, Bacillus Calmette-Guerin (BCG), yellow&#xD;
             fever, varicella and TY21a typhoid vaccines&#xD;
&#xD;
          -  Patients must have Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 1&#xD;
&#xD;
          -  Patients must have life expectancy &gt;= 12 weeks&#xD;
&#xD;
          -  Patients should be advised to avoid drugs or foods that are known potent cytochrome&#xD;
             P450, family 3, subfamily A, polypeptide 4 (CYP3A4) inhibitors or inducers&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          -  Patients have received prior everolimus&#xD;
&#xD;
          -  Patients have either clinically apparent central nervous system metastases or&#xD;
             carcinomatous meningitis =&lt; 6 months prior to randomization&#xD;
&#xD;
          -  Women are pregnant or breast-feeding; all females of childbearing potential must have&#xD;
             a blood test within 2 weeks prior to randomization to rule out pregnancy&#xD;
&#xD;
          -  Patients are on chronic treatment with corticosteroids or other immunosuppressive&#xD;
             agents; topical or inhaled corticosteroids are allowed&#xD;
&#xD;
          -  Patients have history of allergic reactions attributed to compounds of similar&#xD;
             chemical or biologic composition to everolimus&#xD;
&#xD;
          -  Patients have known intolerance or hypersensitivity to everolimus or other rapamycin&#xD;
             analogs (e.g. sirolimus, temsirolimus)&#xD;
&#xD;
          -  Patients have absorption issues that would limit the ability to absorb everolimus&#xD;
&#xD;
          -  Patients have a history of non-compliance to medical regimens or who are considered&#xD;
             potentially unreliable or will not be able to complete the entire study&#xD;
&#xD;
          -  Patients have previous or concurrent malignancy; exceptions are made for patients who&#xD;
             meet any of the following conditions:&#xD;
&#xD;
               -  Non-melanoma skin cancer, in situ cervical cancer, breast cancer in situ, or&#xD;
                  superficial bladder cancer (noninvasive papillary carcinoma or carcinoma in&#xD;
                  situ); OR&#xD;
&#xD;
               -  Prior malignancy completely excised or removed and patient has been continuously&#xD;
                  disease free for &gt; 5 years&#xD;
&#xD;
          -  Patients have severe and/or uncontrolled medical conditions such as:&#xD;
&#xD;
               -  Unstable angina pectoris, symptomatic congestive heart failure, myocardial&#xD;
                  infarction =&lt; 6 months prior to randomization, serious uncontrolled cardiac&#xD;
                  arrhythmia, or any other clinically significant cardiac disease&#xD;
&#xD;
               -  Symptomatic congestive heart failure of New York Heart Association class III or&#xD;
                  IV&#xD;
&#xD;
               -  Active (acute or chronic) or uncontrolled severe infection, liver disease such as&#xD;
                  cirrhosis, decompensated liver disease, and chronic hepatitis (i.e. quantifiable&#xD;
                  hepatitis B virus [HBV]-deoxyribonucleic acid [DNA] and/or positive hepatitis B&#xD;
                  surface antigen [HbsAg], quantifiable hepatitis C virus [HCV]-ribonucleic acid&#xD;
                  [RNA])&#xD;
&#xD;
               -  Active, bleeding diathesis&#xD;
&#xD;
          -  Patients have known history of human immunodeficiency virus (HIV) seropositivity&#xD;
&#xD;
          -  Patients have experienced thrombotic events (deep vein thrombosis, pulmonary embolism)&#xD;
             =&lt; 3 months prior to randomization&#xD;
&#xD;
          -  Patients have liver disease such as cirrhosis, chronic active hepatitis, or chronic&#xD;
             persistent hepatitis at randomization; patients at increased risk for hepatitis B or&#xD;
             hepatitis C must be screened for hepatitis prior to randomization&#xD;
&#xD;
          -  Patients have ongoing cardiac dysrhythmia of National Cancer Institute (NCI) Common&#xD;
             Terminology Criteria for Adverse Events (CTCAE) version 4.0 (v4.0) grade &gt;= 2,&#xD;
             uncontrolled atrial fibrillation of any grade, or corrected QT (QTc) interval &gt; 470&#xD;
             msec&#xD;
&#xD;
          -  Patients have history of severely impaired pulmonary function for their age&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Libutti</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eastern Cooperative Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ecog-Acrin</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>January 7, 2014</study_first_submitted>
  <study_first_submitted_qc>January 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2014</study_first_posted>
  <results_first_submitted>August 24, 2017</results_first_submitted>
  <results_first_submitted_qc>December 1, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 2, 2020</results_first_posted>
  <last_update_submitted>December 1, 2020</last_update_submitted>
  <last_update_submitted_qc>December 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>everolimus</keyword>
  <keyword>randomized</keyword>
  <keyword>metastatic pancreatic neuroendocrine tumors</keyword>
  <keyword>liver</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Insulinoma</mesh_term>
    <mesh_term>Carcinoma, Islet Cell</mesh_term>
    <mesh_term>Gastrinoma</mesh_term>
    <mesh_term>Glucagonoma</mesh_term>
    <mesh_term>Somatostatinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol: Study protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 21, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/36/NCT02031536/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 21, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/36/NCT02031536/ICF_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan: 9. Statistical Considerations</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 21, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/36/NCT02031536/Prot_SAP_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was activated on January 17, 2014 and closed to accrual on March 30, 2015. Two patients, both from Stanford University, were randomized to the trial.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm A (Everolimus)</title>
          <description>Patients receive everolimus PO QD on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.&#xD;
everolimus: Given PO</description>
        </group>
        <group group_id="P2">
          <title>Arm B (Placebo)</title>
          <description>Patients receive placebo PO QD on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.&#xD;
placebo: Given PO</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>ineligible</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All enrolled patients</population>
      <group_list>
        <group group_id="B1">
          <title>Arm A (Everolimus)</title>
          <description>Patients receive everolimus PO QD on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.&#xD;
everolimus: Given PO</description>
        </group>
        <group group_id="B2">
          <title>Arm B (Placebo)</title>
          <description>Patients receive placebo PO QD on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.&#xD;
placebo: Given PO</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Age between 45-49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Disease Free Survival (DFS)</title>
        <description>DFS is defined as time from randomization to disease recurrence or death, whichever occurred first. Patients who are still alive are censored at the last date of known free of recurrence.</description>
        <time_frame>assessed every 12 weeks while on treatment and then every 3 months if &lt; 2 years from study entry; every 6 months up to 5 years from study entry or recurrence, whichever occurred first</time_frame>
        <population>All enrolled patients</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Everolimus)</title>
            <description>Patients receive everolimus PO QD on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.&#xD;
everolimus: Given PO</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Placebo)</title>
            <description>Patients receive placebo PO QD on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.&#xD;
placebo: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Free Survival (DFS)</title>
          <description>DFS is defined as time from randomization to disease recurrence or death, whichever occurred first. Patients who are still alive are censored at the last date of known free of recurrence.</description>
          <population>All enrolled patients</population>
          <units>years</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="NA" upper_limit="NA">There are only 2 patients on this study, and the confidence interval for the median can not be calculated. Full range would reveal patient individual data.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>OS is defined as time from randomization to death from any cause. Patients who are still alive are censored at the last date of known alive.</description>
        <time_frame>assessed every 3 months if &lt; 2 years from study entry, and every 6 months up to 5 years from study entry or death, whichever occurred first</time_frame>
        <population>All enrolled patients</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Everolimus)</title>
            <description>Patients receive everolimus PO QD on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.&#xD;
everolimus: Given PO</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Placebo)</title>
            <description>Patients receive placebo PO QD on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.&#xD;
placebo: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>OS is defined as time from randomization to death from any cause. Patients who are still alive are censored at the last date of known alive.</description>
          <population>All enrolled patients</population>
          <units>years</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.05" lower_limit="NA" upper_limit="NA">There are only 2 patients on this study, and the confidence interval for the median can not be calculated.Full range would reveal patient individual data.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were assessed at the end of each cycle (1 cycle=4 weeks) and at 30 days after the completion of protocol therapy</time_frame>
      <desc>Only grades 4-5 hematologic events and grades 3-5 non-hematologic events were reportable on this study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm A (Everolimus)</title>
          <description>Patients receive everolimus PO QD on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.&#xD;
everolimus: Given PO</description>
        </group>
        <group group_id="E2">
          <title>Arm B (Placebo)</title>
          <description>Patients receive placebo PO QD on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.&#xD;
placebo: Given PO</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Neutrophil count decrease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Statistician</name_or_title>
      <organization>ECOG-ACRIN Statistical Office</organization>
      <phone>617-632-3012</phone>
      <email>eatrials@jimmy.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

